Vaxinano develops life-changing vaccines and immunotherapies for zoonosis and infectious diseases. The company specializes in novel stable non adjuvanted vaccines that aim to combat difficult pathogens.

Vaxinano

Vaxinano is a clinical-stage biotech company that develops vaccines and immunotherapies for zoonosis and infectious diseases. The company is focused on creating non-adjuvanted nasal vaccines that activate the immune system against difficult pathogens.

Vaxinano | 1,284 followers on LinkedIn. Developing life-changing vaccines and immunotherapies | Vaxinano is a clinical-stage biotechnology company, developing a new generation of nasally administered vaccines that are more efficient and faster to deploy to combat infectious diseases and new pandemics. 

The vaccine is based on STELLAR-NP nanoparticles that confer highly stable, adjuvant-free solution for an effective and long-lasting response tot protect against the most difficult pathogens, such as parasites, viruses or bacteria...

Partner in VC fund, in charge of Life Science Investments

Nicolas Roberti

Head of Vaccine Development & Bioproduction - Vaxinano

Angelo Scuotto

R&D Laboratory Manager @ Vaxinano

Romain Magnez

founder of VAXINANO, inventor & developer

Didier Betbeder

💥 Big news in the fight against infectious diseases and new pandemics ! 💉🦠 Vaxinano has raised €6 million 💶 in a funding round led by TCD Capital, Captech Santé, Nord France Amorçage (NFA), Wiseed and a group of business angels, with support from BPI France. These funds will help us propel our flagship vaccines and immunotherapies against leishmaniasis, toxoplasmosis, and other infectious diseases into clinical trials 🌍. Thanks to our groundbreaking Stellar-NP technology 🌟, we are developing a new generation of stable, adjuvant-free nasal vaccines and needle free offering long-lasting protection against the most challenging pathogens, while making vaccination easier and more accessible 💪. 🎯 "This funding marks a major milestone for the commercialization of our vaccine platform and for advancing our vaccines into the clinical phase," said Jonathan Stauber, CEO and Didier Betbeder , Founder & CSO of Vaxinano. Thank you to all our investors for their invaluable support! 🙌 visit our website to learn more about our technologies : www.vaxinano.com ---------- Vaxinano a levé 6 millions d’euros 💶 lors d’un tour de table mené par TCD Capital (ex TheClubDeal) , CAPTECH Santé , Nord France Amorçage (NFA), WiSEED et un groupe de business angels, avec le soutien de Bpifrance . Ces fonds vont nous permettre de propulser nos vaccins phares et nos immunothérapies contre la leishmaniose, la toxoplasmose et autres maladies infectieuses vers les essais cliniques 🌍. Grâce à notre technologie unique Stellar-NP 🌟, nous développons une nouvelle génération de vaccins à administration nasale, stables, sans adjuvant et sans aiguille pour des réponses durables contre les pathogènes les plus complexes, tout en rendant la vaccination plus simple et accessible 💪. 🎯 "Ce financement marque une étape cruciale pour la commercialisation de notre plateforme vaccinale et le passage de nos vaccins à la phase clinique", ont déclarés Jonathan Stauber, CEO et Didier Betbeder, fondateur et CSO de Vaxinano. Merci à nos nouveaux investisseurs et les anciens toujours fidèles pour leur soutien précieux ! 🙌 Eurasanté , Réseau Entreprendre , SATT Nord , Recherche - Université de Lille #Vaccine #OneHealth #InfectiousDiseases #NasalVaccine #Deeptech #Vaxinano

🎃 Spooky Science Alert for Halloween! 🎃 While ghosts and ghouls make their annual rounds, there's something scarier lurking in the real world: zoonotic diseases. 🧬 This recent publications shed light on how pathogens crossing from animals to humans are a rising threat, fueling outbreaks that can impact us all. Vaxinano is on a mission to make sure these "horrors" stay contained. By developing innovative vaccines targeting zoonoses, we’re working to protect both animals and humans from these invisible intruders. So this Halloween, remember: the scariest monsters don’t wear masks—they hide in plain sight. And thanks to science, we’re here to keep them at bay. 🧪 👻 Stay safe, stay protected, and Happy Halloween from Vaxinano! 👻 Link to the publications https://lnkd.in/e9TNn2Pk https://lnkd.in/eAmwGnYT #HalloweenScience #Zoonoses #Vaxinano #AnimalHealth #HumanHealth #ZoonoticDiseases #VaccineInnovation

✨ Vaxinano is proud to share its latest scientific publication in PLOS ONE. 📚 In this study, we developed an improved protocol to evaluate the cellular response induced by Toxoplasma gondii infection in humans. Using an ELISPOT analysis, we demonstrated that the infection triggers a Th1/Th17 response, characterized by the secretion of IFN-γ, IL-2, IL-12, and IL-17. 🧪🔬 This is an important milestone in assessing the efficacy of our vaccine candidate against toxoplasmosis as we move towards future clinical trials, according to Prof. Didier Betbeder. 💉🔝 Read the full article here: 🔗 Link to the article https://lnkd.in/eDtzUYaG #Toxoplasmosis #ELISPOT #Vaccine 💡

🦟 La leishmaniose, est-ce la nouvelle dengue ou le chikungunya ? 🌍 L’Agence Régionale de Santé souligne une menace grandissante dans nos régions : la propagation des phlébotomes, ces insectes capables de transmettre la leishmaniose, une maladie grave touchant les animaux et pouvant se transmettre à l’homme. Avec des cas qui apparaissent de plus en plus au nord de l'Europe, cette maladie pourrait bien devenir aussi préoccupante que la dengue ou le chikungunya. Chez Vaxinano, nous sommes en première ligne dans cette lutte. Grâce à notre plateforme innovante STELLAR-NP, nous travaillons au développement d'un traitement immuno-thérapeutique vaccin nasal contre la leishmaniose. Ce vaccin thérapeutique est crucial non seulement pour protéger les chiens, qui jouent un rôle clé dans la transmission, mais aussi pour réduire les risques pour la santé humaine. 💡 Avec une approche sans aiguilles, nous offrons une solution pratique et efficace, particulièrement adaptée aux zones à risque. La leishmaniose est une menace émergente qui nécessite des actions rapides et efficaces. Chez Vaxinano, nous croyons que l’innovation scientifique peut faire la différence. 📢 Vous souhaitez en savoir plus ou collaborer avec nous ? Contactez-nous pour explorer ensemble des solutions durables ! Le lien ici : https://lnkd.in/gsavupnF #Leishmaniose #NasalVaccin #SantéPublique #Vaxinano #InnovationBiotech #Phlébotomes #Prévention

🌍 Exciting News from Toronto! 🌍 We are thrilled to announce Vaxinano’s participation at the EAZWV/AAZV conference in Toronto, represented by Dr. Kévin Schlax , a talented veterinarian from Saint-Quentin zoo (France). Kevin presented the groundbreaking work we've accomplished together on our innovative nasal toxoplasmosis vaccine. The vaccination of lemurs and wallabies managed an epizootic toxoplasmosis outbreak. This is a major milestone in our mission to tackle this important zoonotic disease. We are proud of this collaboration and excited about the future possibilities in the field of animal health. Stay tuned for more updates! 💉 #Vaccines #AnimalHealth #Innovation #EAZW2024 #AAZV2024 #Vaxinano#wildlifeconservation# ________________________________________ Version française : 🌍 Nouvelles enthousiasmantes de Toronto ! 🌍 Nous sommes ravis d’annoncer la participation de Vaxinano au congrès EAZWV/AAZV à Toronto, représentée par le Dr. Kévin Schlax , un vétérinaire talentueux du zoo de Saint-Quentin (France). Kevin a présenté les travaux révolutionnaires que nous avons réalisé ensemble sur notre vaccin innovant nasal contre la toxoplasmose. La vaccination des lémuriens et des wallabies a permis de gérer une épidémie de toxoplasmose épizootique mortelle. Il s'agit d'une étape importante dans notre mission de lutte contre cette zoonose majeure. Nous sommes fiers de cette collaboration et enthousiastes quant aux futures possibilités dans le domaine de la santé animale. Restez connectés pour plus de nouvelles ! 💉 #Vaccins #SantéAnimale #Innovation #EAZW2024 #AAZV2024 #Vaxinano #wildlifeconservation

🚀 Vaxinano reaches a key milestone! 🚀 We are thrilled to announce the completion of GMP production for our unique nasal vaccine solution , Stellar-NP! 💉🌟 This groundbreaking technology is now available for collaborations and partnerships with pharmaceutical companies. Stellar-NP offers a cost-effective, thermostable, and highly efficient solution for vaccine delivery. If you're looking to innovate in vaccine development, now is the perfect time to partner with us! 🌍💡 Visit our website : www.vaxinano.com #Vaccines #Pharma #Innovation #vaccinano #NasalVaccine #StellarNP #GMP #Thermostablevaccine

🌟 FluMist: Leading the Way for Nasal Vaccine Innovation 🌟 Did you know that FluMist, the nasal spray flu vaccine, is paving the way for a whole new frontier in vaccine technology? 🌍💡 As we continue to seek innovative methods to protect global health, nasal vaccines are emerging as a promising solution, not only for flu but potentially for other infectious diseases too. At Vaxinano, we are proud to be at the forefront of this evolution with our Stellar-NP platform. By developing cutting-edge nasal vaccines, we are contributing to the future of easy, non-invasive immunization that could transform the way we approach disease prevention. 🚀🧬 Follow us on linkedin and www.vaxinano.com Learn more about the exciting potential of nasal vaccines in this insightful article: https://lnkd.in/e-_p7kvJ #NasalVaccines #Innovation #FluMist #VaccineTechnology #Healthcare #Vaxinano #GlobalHealth #InnovationInHealth

🌍 The Future of Vaccines: Targeting Human Parasites 🌍 As countries start vaccinating children against malaria, a new era in vaccine development is on the horizon. There is growing optimism that vaccines targeting other human parasites could soon become a reality, offering hope for millions affected by diseases like schistosomiasis, leishmaniasis, and more. At Vaxinano, we are excited about these advancements and remain committed to using nanotechnology to create innovative solutions that protect global health. Together, we can shape the next wave of vaccines that will combat the most challenging diseases of our time. Link to the Gavi publications : https://lnkd.in/eKpdKMcB Follow our page to learn how we fight parasitosis and zoonosis www.vaxinano.com #Vaxinano #VaccineInnovation #HumanParasites #Nanotechnology #GlobalHealth #MalariaVaccine #FutureOfVaccines

Metric
Company Name	Vaxinano
Symbol
MSH ID	COM:VAXINANO
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	FR
Stage
Employee Count
Website	vaxinano.com
LinkedIn	vaxinano
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

VAXI

COM:VAXINANO

Vaxinano

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue